- 全部删除
- 您的购物车当前为空
Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker and it is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate and it also has a prominent central blocking effect on M1 receptors[2]. Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty. Whereas biperiden and procyclidine did not [3]. Clinical indications: parkinsonism FDA Approved Date: Toxicity: Drowsiness; vertigo; headache; dizziness
Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker and it is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate and it also has a prominent central blocking effect on M1 receptors[2]. Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty. Whereas biperiden and procyclidine did not [3]. Clinical indications: parkinsonism FDA Approved Date: Toxicity: Drowsiness; vertigo; headache; dizziness
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | ¥ 2,690 | 35日内发货 | |
50 mg | ¥ 11,500 | 35日内发货 |
产品描述 | Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker and it is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate and it also has a prominent central blocking effect on M1 receptors[2]. Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty. Whereas biperiden and procyclidine did not [3]. Clinical indications: parkinsonism FDA Approved Date: Toxicity: Drowsiness; vertigo; headache; dizziness |
别名 | 盐酸比哌立登, KL 373 (Hydrochloride) |
分子量 | 347.92 |
分子式 | C21H30ClNO |
CAS No. | 1235-82-1 |
密度 | 1.31g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
溶解度信息 | H2O: 5 mg/mL (14.37 mM), Sonication is recommended. | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
H2O
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容